Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAgile Thrpe

Agile Thrpe

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2024-09-30T06:06:17.584497Z
Market Cap
4.90M
P/E
0.27

Momentum Score

…

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.65
Low
16.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
19.98M
Revenue Per Share
12.32
Gross Profit TTM
-6.62M
Debt / Equity
-0.40
ROE
-1364.04%
Net Debt
-3.04M
ROCE
-4846.08%
Diluted EPS TTM
7.31

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -30.09M -74.89M -51.85M -18.61M -20.26M
Net income -25.41M -76.58M -54.69M -18.44M -19.78M
Selling general administrative 11.86M 14.70M 12.73M 9.00M 8.74M
Selling and marketing expenses 30.37M 43.44M 23.29M - -
Gross profit 4.05M -6.62M 0.47M - 0.00M
Reconciled depreciation 1.53M 2.22M 0.28M 0.16M 0.02M
Ebit -41.43M -71.00M -49.05M -18.86M -18.17M
Ebitda -41.35M -70.98M -48.74M -18.61M -18.15M
Depreciation and amortization 0.08M 0.03M 0.31M 0.25M 0.02M
Non operating income net other - - 0.31M 0.25M 0.40M
Operating income -41.43M -71.00M -49.05M -18.86M -19.54M
Other operating expenses 52.32M 75.11M 49.80M 18.86M 18.52M
Interest expense 3.13M 3.91M 3.11M 0.00M 1.12M
Tax provision -4.67M - 0.00M 0.00M -0.48M
Interest income 0.08M 0.03M 0.31M 0.25M 0.37M
Net interest income -3.05M -3.89M -2.80M 0.25M -0.75M
Non recurring - - - - 1.02M
Income tax expense -4.67M 1.69M 2.83M -0.16M -0.48M
Total revenue 10.88M 4.10M 0.75M 0.00M 0.00M
Total operating expenses 45.48M 64.39M 49.52M 18.86M 18.52M
Cost of revenue 6.84M 10.72M 0.28M - 0.00M
Total other income expense net 11.35M -3.89M -2.80M 0.25M -0.99M
Net income from continuing ops -25.41M -74.89M -51.85M -18.61M -19.78M
Net income applicable to common shares - -74.89M -51.85M -18.61M -19.78M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 14.24M 39.33M 73.06M 49.54M 22.39M
Other current assets 1.40M 1.51M 1.45M 0.18M 0.61M
Total liab 19.79M 30.06M 23.73M 3.79M 2.22M
Total stockholder equity -5.54M 9.27M 49.33M 45.74M 20.17M
Other current liab 3.91M 3.56M 3.35M 1.80M 1.34M
Common stock 0.00M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.00M 0.01M 0.01M 0.01M 0.00M
Retained earnings -408.70M -387.12M -312.22M -260.37M -241.55M
Other assets - 2.01M 1.90M 0.18M 0.02M
Cash 5.25M 19.14M 14.46M 34.48M 7.85M
Total current liabilities 13.39M 29.28M 7.35M 3.79M 2.22M
Net debt -3.04M -1.35M 2.06M -34.31M -7.85M
Short term debt 1.75M 17.01M 0.14M 0.17M -
Short long term debt 1.43M 16.83M - 0.17M -
Short long term debt total 2.21M 17.79M 16.52M 0.17M -
Other stockholder equity 403.15M 396.38M 361.54M 306.11M 262.09M
Property plant equipment - 13.40M 14.24M 14.04M 13.93M
Total current assets 11.36M 23.93M 56.78M 35.32M 8.46M
Net tangible assets - 9.27M 49.33M 45.74M 20.17M
Short term investments - 0.00M 40.01M - -
Net receivables 3.38M 1.53M 0.86M - -
Long term debt - - 16.38M - -
Inventory 1.33M 0.97M - - -
Accounts payable 7.73M 8.71M 3.87M 1.82M 2.22M
Accumulated other comprehensive income - - 0.00M -0.39M -0.37M
Common stock total equity - - 0.01M 0.01M 0.00M
Retained earnings total equity - - -312.00M -260.37M -241.55M
Non currrent assets other 2.01M 2.01M 1.90M 0.18M 0.02M
Non current assets total 2.88M 15.41M 16.28M 14.22M 13.93M
Capital lease obligations 0.79M 0.96M 0.14M 0.17M -
Long term debt total - - 16.38M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.13M 39.46M -40.34M -0.10M -0.32M
Change to liabilities - 5.20M 3.64M 1.38M -1.18M
Total cashflows from investing activities - 39.46M -40.69M -0.10M -0.32M
Net borrowings - - 18.94M 20.00M -10.89M
Total cash from financing activities 22.18M 30.42M 67.98M 42.41M -10.89M
Change to operating activities - -1.10M -2.67M -0.39M 0.15M
Net income -25.41M -74.89M -51.85M -18.61M -19.78M
Change in cash -13.90M 4.68M -20.02M 26.63M -28.10M
Begin period cash flow 19.14M 14.46M 34.48M 7.85M 35.95M
End period cash flow 5.25M 19.14M 14.46M 34.48M 7.85M
Total cash from operating activities -35.95M -65.20M -47.31M -15.69M -16.89M
Issuance of capital stock 39.56M 30.35M 48.43M 42.25M 0.00M
Depreciation 1.53M 2.22M 0.28M 0.16M 0.02M
Change to inventory -0.37M -6.29M -3.64M -6.29M -6.29M
Change to account receivables -1.84M -0.67M -0.86M -0.86M -0.86M
Sale purchase of stock - - 49.04M 42.41M -
Other cashflows from financing activities 4.13M 0.07M 19.55M 0.16M -0.32M
Change to netincome - 10.32M 4.16M 1.76M 3.60M
Capital expenditures 0.13M 0.27M 0.35M 0.10M 0.32M
Change receivables - - -0.86M - -
Cash flows other operating - - -2.67M -0.39M 0.15M
Cash and cash equivalents changes - - -20.02M 26.63M -28.10M
Change in working capital -2.13M -2.85M 0.11M 0.99M -1.02M
Stock based compensation 2.49M 3.34M 2.82M 1.76M 3.63M
Other non cash items -12.43M 1.66M 1.34M -24.29M 0.28M
Free cash flow -36.08M -65.47M -47.66M -15.79M -17.21M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Agile Thrpe

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

500 College Road East, Princeton, NJ, United States, 08540

609 683 1880

https://www.agiletherapeutics.com

22

Name Title Year Born
Mr. Alfred F. Altomari Chairman & CEO 1959
Mr. Geoffrey P. Gilmore Chief Admin. Officer 1966
Dr. Paul Korner M.B.A., M.D. Sr. VP & Chief Medical Officer 1966
Mr. Jason Butch Principal Financial Officer, VP & Chief Accounting Officer NA
Matthew Riley Head of Investor Relations & Corp. Communications NA
Mr. Robert G. Conway M.E. Chief Corp. Planning & Supply Chain Officer 1957
Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H. Consultant 1968
Ms. Amy Welsh Chief Commercial Officer NA
Joseph D'Urso Controller NA
Dr. Kathryn MacFarlane Pharm.D. Advisor 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…